https://www.jnj.com/media-center/press-releases/european-commission-approves-johnson-johnsons-subcutaneous-darzalex-daratumumab-based-quadruplet-regimen-for-the-therapy-of-patients-with-newly-diagnosed-multiple-myeloma-regardless-of-transplant-eligibility